Tissue | Expression Dynamics | Abbreviation |
Cervix | | CC: Cervix cancer |
HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions |
N_HPV: HPV-infected normal cervix |
Colorectum (GSE201348) | | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Esophagus | | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Oral Cavity | | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Thyroid | | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:003009910 | Cervix | CC | myeloid cell differentiation | 83/2311 | 381/18723 | 1.31e-07 | 6.42e-06 | 83 |
GO:0030099 | Colorectum | AD | myeloid cell differentiation | 119/3918 | 381/18723 | 1.24e-06 | 4.01e-05 | 119 |
GO:00300992 | Colorectum | MSS | myeloid cell differentiation | 110/3467 | 381/18723 | 4.48e-07 | 1.75e-05 | 110 |
GO:00300994 | Colorectum | FAP | myeloid cell differentiation | 81/2622 | 381/18723 | 6.33e-05 | 1.22e-03 | 81 |
GO:00300995 | Colorectum | CRC | myeloid cell differentiation | 66/2078 | 381/18723 | 1.59e-04 | 2.87e-03 | 66 |
GO:0030099111 | Esophagus | ESCC | myeloid cell differentiation | 232/8552 | 381/18723 | 1.22e-09 | 2.90e-08 | 232 |
GO:000635211 | Esophagus | ESCC | DNA-templated transcription, initiation | 86/8552 | 130/18723 | 1.88e-06 | 2.19e-05 | 86 |
GO:00300997 | Liver | NAFLD | myeloid cell differentiation | 55/1882 | 381/18723 | 3.86e-03 | 3.28e-02 | 55 |
GO:0006352 | Liver | HCC | DNA-templated transcription, initiation | 78/7958 | 130/18723 | 4.19e-05 | 4.11e-04 | 78 |
GO:003009922 | Liver | HCC | myeloid cell differentiation | 200/7958 | 381/18723 | 4.64e-05 | 4.49e-04 | 200 |
GO:003009920 | Oral cavity | OSCC | myeloid cell differentiation | 213/7305 | 381/18723 | 1.24e-11 | 4.42e-10 | 213 |
GO:00063522 | Oral cavity | OSCC | DNA-templated transcription, initiation | 74/7305 | 130/18723 | 2.56e-05 | 2.39e-04 | 74 |
GO:003009926 | Oral cavity | EOLP | myeloid cell differentiation | 91/2218 | 381/18723 | 2.87e-11 | 4.15e-09 | 91 |
GO:003009932 | Oral cavity | NEOLP | myeloid cell differentiation | 83/2005 | 381/18723 | 1.79e-10 | 1.69e-08 | 83 |
GO:0030099113 | Thyroid | PTC | myeloid cell differentiation | 160/5968 | 381/18723 | 1.75e-05 | 1.82e-04 | 160 |
GO:00063525 | Thyroid | PTC | DNA-templated transcription, initiation | 63/5968 | 130/18723 | 5.72e-05 | 5.05e-04 | 63 |
GO:003009933 | Thyroid | ATC | myeloid cell differentiation | 170/6293 | 381/18723 | 4.26e-06 | 4.68e-05 | 170 |
GO:000635213 | Thyroid | ATC | DNA-templated transcription, initiation | 64/6293 | 130/18723 | 1.60e-04 | 1.10e-03 | 64 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
NCOA6 | SNV | Missense_Mutation | | c.4115N>C | p.Arg1372Thr | p.R1372T | Q14686 | protein_coding | deleterious(0.01) | possibly_damaging(0.813) | TCGA-A2-A0CX-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD |
NCOA6 | SNV | Missense_Mutation | | c.4670C>T | p.Ser1557Leu | p.S1557L | Q14686 | protein_coding | deleterious(0.03) | benign(0.115) | TCGA-A8-A07G-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | 5-fluorouracil | CR |
NCOA6 | SNV | Missense_Mutation | | c.1375N>G | p.Gln459Glu | p.Q459E | Q14686 | protein_coding | deleterious_low_confidence(0) | probably_damaging(0.931) | TCGA-A8-A094-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
NCOA6 | SNV | Missense_Mutation | rs370273117 | c.5423G>A | p.Arg1808Gln | p.R1808Q | Q14686 | protein_coding | deleterious_low_confidence(0.01) | possibly_damaging(0.901) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
NCOA6 | SNV | Missense_Mutation | novel | c.5524G>A | p.Gly1842Arg | p.G1842R | Q14686 | protein_coding | deleterious_low_confidence(0.01) | possibly_damaging(0.659) | TCGA-AC-A8OQ-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
NCOA6 | SNV | Missense_Mutation | | c.964N>G | p.Pro322Ala | p.P322A | Q14686 | protein_coding | tolerated(0.14) | benign(0.011) | TCGA-AN-A041-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
NCOA6 | SNV | Missense_Mutation | rs143707360 | c.6103N>T | p.Arg2035Cys | p.R2035C | Q14686 | protein_coding | deleterious_low_confidence(0) | possibly_damaging(0.719) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
NCOA6 | SNV | Missense_Mutation | novel | c.4270N>A | p.Asp1424Asn | p.D1424N | Q14686 | protein_coding | deleterious(0.01) | possibly_damaging(0.452) | TCGA-BH-A0B6-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
NCOA6 | SNV | Missense_Mutation | | c.223N>G | p.Leu75Val | p.L75V | Q14686 | protein_coding | tolerated(0.11) | possibly_damaging(0.496) | TCGA-BH-A0BZ-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | doxorubicin | CR |
NCOA6 | SNV | Missense_Mutation | | c.5384N>T | p.Pro1795Leu | p.P1795L | Q14686 | protein_coding | deleterious_low_confidence(0) | possibly_damaging(0.518) | TCGA-BH-A0HF-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD |